Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.
These plasma products are produced to the highest standards, using the latest technology, in state of the art manufacturing facilities to ensure the most advance solutions are available to patients globally.
"Bleeding disorder" is a general term for a wide range of medical problems that lead to poor blood clotting and continuous bleeding, including:
- Haemophilia A
- Haemophilia B
- von Willebrand disease (VWD)
In people with such disorders, clotting factors like Factor VIII, Factor IX or von Willebrand factor (VWF) are missing or don't work as they should. This causes these people to bleed for a longer time than those whose blood factor levels are normal. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.
Please watch the video to get acquainted with a story from one of the patient.
High-purity human Factor VIII / von Willebrand Factor (VWF) concentrate for prophylaxis and treatment of bleeding in patients with Haemophilia A. Octanate undergoes two independent virus-inactivation steps (solvent/detergent treatment and terminal dry heat for 30 minutes at 100°C).
High-purity human von Willebrand Factor (VWF)/Factor VIII concentrate with the native VWF/FVIII complex in physiological 1:1 ratio and two independent virus inactivation steps (solvent/detergent treatment and terminal dry heat at 100°C for 120 min) for the treatment of patients with von Willebrand disease (VWD) and Haemophilia A.
High-purity human Factor IX concentrate with two independant virus inactivation and removal steps (solvent/detergent treatment and nanofiltration) for the prophylaxis and treatment of bleeding in patients with haemophilia B.